|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00955227 |
|
Date of registration:
|
06/08/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels
|
|
Scientific title:
|
Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels |
|
Date of first enrolment:
|
July 2009 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00955227 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
|
|
|
Countries of recruitment
|
|
Canada
| | | | | | | |
|
Contacts
|
|
Name:
|
Davinder Jassal |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
St. Boniface General Hospital Research Centre |
|
|
Name:
|
Grant N Pierce, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
St. Boniface General Hospital Research Centre |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- The subject is between 18-80 years old
- The subject lives in Winnipeg area
- The subject is willing to seize intake of oils/ salad dressings/ seafood
- The subject is willing to comply with the study schedule
Exclusion Criteria:
- The subject had been taking flax oil in the last month
- The subject is not willing to undergo dietary restrictions
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Hypercholesterolemia
|
|
Hyperlipidemia
|
|
Intervention(s)
|
|
Dietary Supplement: Flax seed oil (ALA)
|
|
Drug: Ezetimibe
|
|
Primary Outcome(s)
|
|
Levels of circulating omega-3 fatty acid (ALA)
[Time Frame: 6 weeks after enrollment of patient]
|
|
Secondary Outcome(s)
|
|
The n6:n3 fatty acid ratio will be calculated Total cholesterol, LDL, HDL, and triglyceride levels will also be measured
[Time Frame: 6 weeks after patient enrollment]
|
|
Secondary ID(s)
|
|
B2009:054
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|